Real-World Total Daily Insulin Dose in over 14,000 Young Individuals with Type 1 Diabetes in the United States
Real-World-Total-Daily-Insulin-Dose bei über 14.000 jungen Menschen mit Typ-1-Diabetes in den USA
Diabetes Technology & Therapeutics · 2026-11-01 · 28 (11) · 1171-1180
DOI: 10.1177/15209156261447653 ↗Auf einen Blick
In einer retrospektiven Analyse von 14.358 jungen Menschen mit Typ-1-Diabetes unterschied sich die tägliche Insulinmenge nach Alter, Geschlecht, BMI, HbA1c und Insulinabgabemethode. Die stärkste Zunahme zeigte sich zwischen 9 und 13 Jahren.
Fragestellung
Wie hoch ist die tägliche Insulindosis bei Kindern, Jugendlichen und jungen Erwachsenen mit Typ-1-Diabetes in Abhängigkeit von Alter, Geschlecht, BMI, HbA1c und Insulinabgabemethode?
Methode
Retrospektive Analyse elektronischer Gesundheitsakten aus dem T1D Exchange Quality Improvement Collaborative bei 2- bis 25-Jährigen mit Typ-1-Diabetes; TDD in IU/kg/Tag nach Alter, Geschlecht, BMI, HbA1c und Insulinabgabemethode stratifiziert.
Ergebnisse
14.358 Personen mit Typ-1-Diabetes. Mittleres Alter 16,2 (4,3) Jahre; 48 % weiblich; 80 % mit kontinuierlichem Glukosemonitoring. Höhere TDD bei höherem BMI und HbA1c sowie unter MDI im Vergleich zu Pumpe und HCLS.
Schlussfolgerung der Autor:innen
Die dynamischen Insulinanforderungen nach Alter, Geschlecht, BMI, HbA1c und Insulinabgabemethode sowie die Schwierigkeit, glykämische Ziele zu erreichen, sprechen für eine häufige Neubewertung der TDD, besonders in der Pubertät.
Kernaussagen
- TDD stieg von 2 bis 13 Jahren, am stärksten zwischen 9 und 13 Jahren
- Bei Frauen lag der TDD-Peak mit 12 Jahren, bei Männern mit 14 Jahren
- Höhere TDD bei höherem BMI, höherem HbA1c und unter MDI
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Journal article in Diabetes Technology & Therapeutics, published online on 2026-05-12. Written by Rebecca L Molinsky and 6 co-authors. Institution: Vertex Pharmaceuticals Inc., Boston, Massachusetts, USA. Major MEDLINE topics: Diabetes Mellitus, Type 1, Insulin, Hypoglycemic Agents. Cited 2 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Objective
Insulin requirements for people with type 1 diabetes (T1D) may vary with changes in age, pubertal status, and weight. There are limited data to assess insulin requirements based on age, sex, and body mass index (BMI) with modern treatment paradigms, especially among those using advanced technologies for the treatment and management of T1D. This study estimated total daily insulin dose (TDD) in children, adolescents, and young adults with T1D. Materials and Methods: This retrospective study analyzed electronic health records of people with T1D aged 2–25 years from the T1D Exchange Quality Improvement Collaborative. TDD (IU/kg/day) was reported and stratified by age, sex, BMI, glycated hemoglobin (HbA1c), and insulin delivery method.
Results
This study included 14,358 people with T1D. Mean (SD) age of 16.2 (4.3) years, 48% were females, 74.6% were White, and 80% used a continuous glucose monitor. Mean HbA1c was 8.4%, and 80.2% of participants had an HbA1c ≥7%. TDD increased from age 2–13 years, with the steepest increase from 9–13 years. In females, the peak TDD was at age 12 years compared to age 14 years for males. Higher TDD was observed among those within higher BMI and HbA1c categories and in multiple daily injections (MDI) users compared to insulin pump (non-hybrid closed loop system [HCLS]) and HCLS users.
Conclusions
Dynamic insulin requirements across age, sex, BMI, HbA1c, and insulin delivery methods, along with difficulty in achieving glycemic targets, highlight the need for frequent reassessment of TDD, especially during puberty.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Vertex Pharmaceuticals Inc., Boston, Massachusetts, USA.
- Joslin Diabetes Center, Boston, Massachusetts, USA.
- T1D Exchange, Boston, Massachusetts, USA.
- Baylor College of Medicine, Houston, Texas, USA.
- University of Mississippi School of Population Health, Jackson, Mississippi, USA.
ORCID profiles: Rebecca L Molinsky
Cite
APA
Molinsky, R. L., Gaglia, J., Zhang, Y., Gupta, T., Rompicherla, S., Dei-Tutu, S. A., & Ebekozien, O. (2026). Real-World Total Daily Insulin Dose in over 14,000 Young Individuals with Type 1 Diabetes in the United States. Diabetes Technology & Therapeutics, 28(11), 1171-1180. https://doi.org/10.1177/15209156261447653
Vancouver
Molinsky RL, Gaglia J, Zhang Y, Gupta T, Rompicherla S, Dei-Tutu SA, et al. Real-World Total Daily Insulin Dose in over 14,000 Young Individuals with Type 1 Diabetes in the United States. Diabetes Technology & Therapeutics. 2026;28(11):1171-1180. doi:10.1177/15209156261447653
BibTeX
@article{Molinsky2026,
author = {Molinsky, Rebecca L and Gaglia, Jason and Zhang, Yumin and Gupta, Tina and Rompicherla, Saketh and Dei-Tutu, Selorm A and Ebekozien, Osagie},
title = {Real-World Total Daily Insulin Dose in over 14,000 Young Individuals with Type 1 Diabetes in the United States},
journal = {Diabetes Technology & Therapeutics},
year = {2026},
volume = {28},
number = {11},
pages = {1171--1180},
doi = {10.1177/15209156261447653}
}
EUVIMED